抗癌平丸联合经导管肝动脉化疗栓塞术治疗中晚期肝癌的系统评价  

Systematic Review on Kang'aiping Pills Combined with Transcatheter Arterial Chemoembolizatio in Treatment of Intermediated or Advanced Liver Cancer

作　　者：吴君 饶东平 宫晓 周仪 张秋 

机构地区：[1]广东药科大学医药经济学院,广东广州510006 [2]江门市中心医院病案科,广东江门529030 [3]广东药科大学公共卫生学院流行病与卫生统计学系,广东广州510310

出　　处：《中国医院用药评价与分析》2018年第2期221-223,227,共4页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:系统评价抗癌平丸联合经导管肝动脉化疗栓塞术(transcatheter arterial chemoembolization,TACE)治疗中晚期肝癌的临床疗效。方法:计算机检索万方数据、中国生物医学文献数据库、中国知网、中文科技期刊数据库、Pubmed、台湾学术文献数据库Airiti Library及香港大学学术库等,纳入有关抗癌平丸联合TACE(观察组)与单纯TACE(对照组)分别治疗中晚期肝癌的随机对照试验,提取资料并进行方法学质量评价后,采用Rev Man 5.3软件进行文献荟萃(Meta)分析。结果:纳入3篇文献,共776例患者。Meta分析结果显示,与对照组比较,抗癌平丸联合TACE治疗可以显著提高中晚期肝癌患者的近期有效率(OR=2.18,95%CI=1.48~3.22,P<0.000 1)、1年生存率(OR=1.87,95%CI=1.30~2.70,P=0.000 8)、2年生存率(OR=2.03,95%CI=1.41~2.92,P=0.000 1)和生活质量改善率(OR=2.87,95%CI=1.35~6.11,P=0.000 6),差异均有统计学意义。结论:抗癌平丸联合TACE治疗可以改善中晚期患者的近期疗效,提高生存率和生活质量。OBJECTIVE： To systematically review the clinical efficacy of Kang＇aiping pills combined with transcatheter arterial chemoembolization（ TACE） in treatment of intermediated or advanced liver cancer. METHODS：Randomized controlled trials on Kang＇aiping pills combined with TACE（ observation group） and TACE alone（ control group） in respective treatment of intermediated or advanced liver cancer were involved by retrieving Wanfang,CBM,CNKI,VIP,Pub Med,Airiti Library in Taiwan and HKU Scholars Hub,methodological quality evaluation was conducted after extracting data,and Rev Man 5. 3 was adopted to carry out Meta analysis. RESULTS： 3 studies including 776 patients were involved. Results of Meta analysis indicated that the combined treatment of Kang＇aiping pills and TACE can significantly promote the short-term effective rate（ OR = 2. 18,95% CI = 1. 48-3. 22,P 〈0. 000 1）,survival rate in 1 year（ OR = 1. 87,95% CI = 1. 30-2. 70,P = 0. 000 8）,survival rate in 2 years（ OR = 2. 03,95% CI = 1. 41-2. 92,P =0. 000 1） and improvement rate of life quality（ OR = 2. 87,95% CI = 1. 35-6. 11,P = 0. 000 6） for patients with intermediated or advanced liver cancer compared with those of the control group,with statistically significant differences.CONCLUSIONS： The combined treatment of Kang＇aiping pills and TACE can significantly improve short-term efficacy for patients with intermediated or advanced liver cancer,promote survival rate and life quality.

关 键 词：抗癌平丸 肝癌 TACE META分析 

分 类 号：R932[医药卫生—生药学] R979.1[医药卫生—药学]